PRESS RELEASE

8 April 2022 **FOR IMMEDIATE RELEASE**

CENGILD G. I. MEDICAL CENTRE
Centre for Gastrointestinal and Liver Diseases

CENGILD MEDICAL BERHAD
(Registration No. 202101004143 (1404442-P)

INITIAL PUBLIC OFFERING ("IPO") OF 218,800,000 NEW ORDINARY SHARES IN CENGILD MEDICAL BERHAD ("CENGILD MEDICAL") ("SHARES") ("IPO SHARES") IN CONJUNCTION WITH THE LISTING OF AND QUOTATION FOR THE ENTIRE ISSUED SHARE CAPITAL OF CENGILD MEDICAL ON THE ACE MARKET OF BURSA MALAYSIA SECURITIES BERHAD

The IPO involves the issuance of 218,800,000 IPO Shares comprising the following:

(i) institutional offering of 162,860,000 IPO Shares to institutional and selected investors, at the institutional price; and

(ii) retail offering of 55,940,000 IPO Shares to the Malaysian public, the eligible directors, eligible key senior management, eligible employees and persons who have contributed to the success of Cengild Medical and its subsidiaries at the retail price.

Tricor Investor & Issuing House Services Sdn Bhd ("**TIIH**") wishes to announce that following the completion of the bookbuilding process under the Institutional Offering on 5 April 2022, the institutional price has been fixed at RM0.33 per IPO Share. Accordingly, the final retail price for the IPO Shares under the Retail Offering has also been fixed at RM0.33 per IPO Share.

As the final retail price equals to the retail price of RM0.33 per IPO Share, there will be no refund to be made to the successful applicants under the Retail Offering.

A total of 17,462 applications for 1,863,985,200 IPO Shares with a value of RM615,115,116.00 were received from the Malaysian public for the 40,940,000 IPO Shares made available for application by the Malaysian public, which represents an overall oversubscription rate of 44.53 times. For the Bumiputera public portion, a total of 8,075 applications for 592,643,800 IPO Shares were received which represents an oversubscription rate of 27.95 times. For the remaining Malaysian public portion, a total of 9,387 applications for 1,271,341,400 IPO Shares were received which represents an oversubscription rate of 61.11 times.

The 15,000,000 IPO shares made available for application by the eligible directors, eligible key senior management, eligible employees and persons who have contributed to the success of Cengild Medical and its subsidiaries were fully subscribed.

For the Institutional Offering, the Sole Bookrunner has confirmed that the 162,860,000 IPO Shares offered to institutional and selected investors have also been fully subscribed.

The notices of allotment will be despatched to all successful applicants on or before 15 April 2022.

Hong Leong Investment Bank Berhad is the Principal Adviser, Sponsor, Sole Underwriter and Sole Bookrunner for the IPO.